Inclusion Criteria:

- Histologically confirmed prostate cancer

- Measurable disease on computed tomography (CT) or evaluable disease on bone scan with
an elevated PSA

- For patients who did not initially present with metastatic disease, definitive
treatment with either radical prostatectomy or external beam radiation is permitted

- Documented progression on (a) two prior hormone treatments AND (b) one or two
chemotherapy regimens

- Documented progression on two prior hormone therapies is defined as orchiectomy
followed by anti-adrenal medication upon progression OR gonadotropin-releasing
hormone (GnRH) analog +/- androgen receptor blocker with addition or subtraction upon
progression; castrate level of testosterone must be documented at study entry

- Documented progression on taxane-based chemotherapy; in addition, patients may have
failed a second prior chemotherapy regimen

- Palliative radiation therapy for metastatic disease is allowed only if less than 25%
of total body bone marrow was irradiated; 28 days must have elapsed since completion
of radiation therapy (RT) with bone marrow recovery; soft tissue disease irradiated
in the prior 2 months may not be designated as measurable disease

- ECOG performance score of 0-2

- Absolute neutrophil count (ANC) >= 1500/uL

- Platelet count >= 100,000/uL

- Creatinine clearance >= 45 mL/min

- Serum total bilirubin =<1.5 mg/dL

- Alkaline phosphatase =< 3x the upper limit of normal (ULN) for the reference lab (=<
5x the ULN for patients with known hepatic metastases) and no upper limit for
patients with known bone metastases

- Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase
(SGPT) =< 3x the ULN for the reference lab (=< 5x the ULN for patients with known
hepatic metastases)

- Patients must be recovered from both acute and late effects of any prior surgery,
radiotherapy or other antineoplastic therapy

- Patients or their legal representatives must be able to read, understand and provide
informed consent to participate in the trial

- Men of childbearing potential must consent to use barrier contraception while on
treatment and for 90 days thereafter

- Patients with pleural or peritoneal effusions are eligible

- Willingness and ability to take vitamin supplementation and steroid premedication as
specified in protocol

- Patients with superficial bladder cancer or skin cancer who have second malignancy
within 5 years which was removed with curative intent

Exclusion Criteria:

- Active infection or with a fever >= 38.5 degrees Celsius (C) within 3 days of the
first scheduled protocol treatment

- Patients with brain metastases

- Prior malignancy within the past 5 years, except for curatively treated basal cell or
squamous cell carcinoma of the skin or superficial bladder cancer

- Known hypersensitivity to any of the components of oxaliplatin or pemetrexed

- Received radiotherapy to more than 25% of their bone marrow, or patients who received
any radiotherapy within 4 weeks of entry

- Received treatment with strontium

- Receiving concurrent investigational therapy or who have received investigational
therapy within 30 days of the first scheduled day of protocol treatment

- Life expectancy < 6 months

- Peripheral neuropathy >= Grade 2

- Any other medical condition, including mental illness or substance abuse

- History of allogeneic transplant

- Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously
treated, or both)

- Inability to stop nonsteroidal anti-inflammatory drugs (NSAIDS) for a period of 2
days before, the day of, and 2 days following administration of Alimta; 5 days
before, the day of, and 2 days following administration of Alimta for long-acting
NSAIDS